InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Explore the full record of transactions filed by Johnson Waynick Denelle, Executive. Director active across 1 company, notably UCB. Aggregated, 3 reports have been published. History available since 1 April 2026. The latest transaction was filed on 1 April 2026 (Purchase). Regulator: FSMA. All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations
Denelle Johnson Waynick is a senior executive at UCB, a biopharmaceutical company. She is responsible for managing operations and product innovation. Her expertise contributes to the growth and reputation of UCB in the market.